Maze Therapeutics, Inc. Common Stock

Day range

$30.71 – $31.67

Open

$30.93

Prev close

$31.01

Volume

140.59K

Market cap

$1.72B

Shares out

55.55M

P/E

—

P/S

86.13

P/B

3.80

P/FCF

—

ROE

-29.5%

ROA

-25.1%

Debt/Equity

0.09

Div yield

0.00%

As of Oct 23, 2026

• Equity compensation grantAug 17, 2026

  In accordance with the Director Compensation Policy, the Board granted to each of Dr. Johnson and Dr. Kornowski, effective as of the Appointment Date, an option to purchase 36,000 shares of the Company's common stock (each, an "Option Award"), with 1/36th of the shares underlying each Option Award vesting and becoming exercisable on each monthly anniversary of the Appointment Date, subject to the applicable director's continued service to the Company.

• Executive officer departureMay 22, 2026

  On May 18, 2026, Amy Bachrodt gave notice that she will resign as Senior Vice President, Finance of Maze Therapeutics, Inc. (the "Company"), effective June 1, 2026. Ms. Bachrodt's resignation was not as a result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices or on any matter relating to the Company's financial reporting.

• Underwriting agreementApr 22, 2026

  Maze Therapeutics, Inc., a Delaware corporation (the "Company"), entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC as sole underwriter (the "Underwriter"), pursuant to which the Company agreed to issue and sell an aggregate of (a) 5,540,000 shares of its common stock (the "Shares") and (b) pre-funded warrants to purchase 850,000 shares of its common stock (the "Pre-Funded Warrants"). The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, conditions to closing, termination provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended (the "Securities Act").

• Equity compensation grantMar 25, 2026

  In connection with Dr. Kumar's appointment as a non-employee director on the Board, he will receive a pro rata portion of the $40,000 annual retainer for service as a director for the remaining portion of the year... the Board granted to Dr. Kumar, effective as of the Appointment Date, an option to purchase the lesser of 36,000 shares of the Company's common stock (the "Option Award") or that number of shares of the Company's common stock resulting in the option having a grant date fair value of $750,000 as of the Appointment Date, with 1/36th of the shares underlying the Option Award vesting and becoming exercisable on each monthly anniversary of the Appointment Date.

• Deal terminationFeb 4, 2026

  In connection with the entry into the Hercules Loan Agreement, the Company's Loan and Security Agreement, dated as of June 27, 2022, with Banc of California was terminated, effective as of February 2, 2026, and Banc of California's security interest in the Company's assets and property was released.

Days to cover

6.1

Short interest

6.57M

Avg volume

1.08M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock
  positiveZacks Investment Research· Oct 19, 2026
• How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%
  positiveZacks Investment Research· Oct 19, 2026
• Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials
  positiveThe Motley Fool· May 7, 2026
• Maze Therapeutics Announces $150 Million Registered Offering
  positiveGlobeNewswire Inc.· Apr 22, 2026
• Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
  neutralThe Motley Fool· Apr 4, 2026